Clinical Study on the Treatment of Foot Cell Injury in Diabetic Nephropathy Patients with Chinese Medicine Xiaoke Decoction

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036692

Enrollment

Unknown

Registered

2020-08-24

Start date

2021-01-01

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

Western medicine control group:Oral valsartan 80mg/ day

Chinese medicine plus western medicine treatment group:Oral valsartan 80mg/ day combined with traditional Chinese medicine "Xiaoketang" compound

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A total of 40 patients aged 30-75 years from January 2020 to September 2021 were collected from the outpatient department of nephropathy of diabetes in our hospital. All of them met the diagnostic criteria of the world health organization (WHO) for DM in 1999 and were diagnosed as diabetic stage iiiiv urinary albumin/urinary creatinine ratio (UACR) >30mg/g according to the Mogensen diabetes staging criteria.

Exclusion criteria

Exclusion criteria: Patients with macrovascular disease, chronic nephritis, congestive heart failure, fever, urinary tract infection, malignant tumor and other diseases were excluded. No recent history of taking nephrotoxic drugs was found.

Design outcomes

Primary

Measure	Time frame
Blood sugar;Serum creatinine;Uroprotein quantification;Nephrin;Podocin;The activity of histone deacetylase (HDAC).;Blood urea nitrogen;Blood uric acid;	—

Countries

China

Contacts

Public ContactTang Zhiqi

Shanghai Traditional Chinese Medicine Hospital

13681766928@163.com+86 13681766928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026